2154. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates from Bloodstream and Respiratory Tract Infections– SMART United States 2019-2021

BACKGROUND: Antimicrobial resistance among Pseudomonas aeruginosa is challenging with limited treatment options. Ceftolozane/tazobactam (C/T) maintains activity against P. aeruginosa resistant to commonly used β-lactams. Imipenem/relebactam (IMI/REL) can restore the activity of IMI against P. aerugi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Wise, Mark G, Bauer, Karri, Siddiqui, Fakhar, Hilbert, David W, Esterly, John, DeRyke, C Andrew, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678284/
http://dx.doi.org/10.1093/ofid/ofad500.1777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678284/
http://dx.doi.org/10.1093/ofid/ofad500.1777

Ejemplares similares